MVision AI’s Contour+ Approved for Clinical Use in Singapore

Published: 9.05.25

Helsinki, May 2025 — MVision AI announces that Contour+, its AI-based auto-contouring software for radiation therapy, has received market approval for clinical use in Singapore. This approval confirms that Contour+ meets the standards required by Singapore’s Health Sciences Authority (HSA), allowing it to be deployed in routine radiation therapy planning across the country.

This development comes at a critical time. Singapore records an average of approximately 48 new cancer cases each day, with males accounting for 49% and females 51% of these cases (1). Furthermore, the Global Cancer Observatory estimates that the cumulative risk of developing cancer before the age of 75 in Singapore is 23.7% for males and 22.1% for females, underscoring the significant lifetime risk faced by the population (2).

As cancer rates rise, the demand for radiation therapy also increases, highlighting the need for technologies that facilitate reliable contouring. Contour+ delivers high-quality anatomical segmentation that supports consistency, speed, and alignment with international guidelines. With the ability to segment over 300 anatomical structures—including 90 lymph node regions—Contour+ is designed to streamline the contouring process and reduce variation between clinicians and institutions.

“Approval in Singapore strengthens our ability to support clinical teams with technology that is both reliable and precise,” said Mahmudul Hasan, Founder and Executive Director of MVision AI. “Our goal is to contribute meaningfully to the standardization of care, ultimately helping clinicians deliver more predictable and patient-centered treatment.”

By reducing manual workload by up to 95% and supporting consistent, guideline-compliant planning, Contour+ brings measurable improvements to radiation therapy treatment planning across Singapore.

MVision AI continues to expand the clinical availability of Contour+ to support standardized radiation therapy planning across global markets.

For more information, visit www.mvision.ai or contact info@mvision.ai.

About MVision AI

MVision AI is a leading provider of AI-powered solutions for radiation therapy treatment planning. Our mission is to empower Radiation Oncology professionals with cutting-edge technology to streamline workflows, enhance treatment quality, and facilitate more patient-focused care. With a commitment to innovation and excellence, MVision AI continues to advance cancer care through the power of AI.